Literature DB >> 22849293

Epigallocatechin-3-gallate modulates antioxidant and DNA repair-related proteins in exocrine glands of a primary Sjogren's syndrome mouse model prior to disease onset.

Seiji Ohno1, Hongfang Yu, Douglas Dickinson, Tin-Chun Chu, Kalu Ogbureke, Scott Derossi, Tetsuya Yamamoto, Stephen Hsu.   

Abstract

The autoimmune disorder primary Sjogren's syndrome (SS) is associated with xerostomia and xerophthalmia. SS pathogenesis involves both genetic/epigenetic and environmental factors. A major potential contributor is oxidative stress associated with damage to cellular components, including DNA. We reported previously that the green tea polyphenol epigallocatechin-3-gallate (EGCG) normalizes the elevated levels of proliferating cell nuclear antigen (PCNA), a key component of DNA repair, in the NOD mouse model for SS and type 1 diabetes. The current study examined levels of the antioxidant enzymes peroxiredoxin 6 (PRDX6), catalase and superoxide dismutase (SOD), as well as PCNA, in NOD.B10.Sn-H2 mice, a model for primary SS, and determined the effect of EGCG on their expression. PCNA elevation was detected in the submandibular gland and pancreas by 8 weeks of age in water-fed mice, and increased through 14 weeks of age, prior to overt onset of symptoms. This early PCNA elevation was followed by a decline of peroxiredoxin 6 protein. In contrast, EGCG-fed mice exhibited normal levels of PCNA and peroxiredoxin 6, comparable to healthy untreated BALB/c mice. Similar patterns were observed in the pancreas, even though these mice do not develop diabetes. Thus, elevated PCNA is an early biomarker for exocrine glandular dysfunction associated with SS-like autoimmune disease, accompanied subsequently by decreased PRDX6 antioxidant enzyme levels that could further contribute to oxidative stress, and these changes precede inflammatory cell infiltration. Importantly, EGCG consumption normalizes the expression of these biomarkers in this model. These observations could lead to early diagnosis and intervention of autoimmune disorders.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22849293     DOI: 10.3109/08916934.2012.710860

Source DB:  PubMed          Journal:  Autoimmunity        ISSN: 0891-6934            Impact factor:   2.815


  7 in total

1.  Epigallocatechin-3-gallate modulates anti-oxidant defense enzyme expression in murine submandibular and pancreatic exocrine gland cells and human HSG cells.

Authors:  Douglas Dickinson; Scott DeRossi; Hongfang Yu; Cristina Thomas; Chris Kragor; Becky Paquin; Emily Hahn; Seiji Ohno; Tetsuya Yamamoto; Stephen Hsu
Journal:  Autoimmunity       Date:  2014-01-20       Impact factor: 2.815

Review 2.  Mouse Models of Primary Sjogren's Syndrome.

Authors:  Young-Seok Park; Adrienne E Gauna; Seunghee Cha
Journal:  Curr Pharm Des       Date:  2015       Impact factor: 3.116

Review 3.  Autoimmunity in 2012.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2013-10       Impact factor: 8.667

4.  Epigallocatechin-3-gallate ameliorates erectile function in aged rats via regulation of PRMT1/DDAH/ADMA/NOS metabolism pathway.

Authors:  Dong Chen; Ke-Qin Zhang; Bo Li; Ding-Qi Sun; Hui Zhang; Qiang Fu
Journal:  Asian J Androl       Date:  2017 May-Jun       Impact factor: 3.285

5.  In Vitro and In Silico Analysis of the Inhibitory Activity of EGCG-Stearate against Herpes Simplex Virus-2.

Authors:  James D Stamos; Lee H Lee; Calvin Taylor; Tony Elias; Sandra D Adams
Journal:  Microorganisms       Date:  2022-07-20

Review 6.  Diagnosis, Prevention, and Treatment of Radiotherapy-Induced Xerostomia: A Review.

Authors:  Yanli Li; Xuehan Li; Runxuan Pang; Guang Yang; Mingxu Tian; Tengyu Zhao; Yunhan Sun; Eui-Seok Lee; Heng Bo Jiang; Jianmin Han
Journal:  J Oncol       Date:  2022-08-27       Impact factor: 4.501

Review 7.  Roles of peroxiredoxins in cancer, neurodegenerative diseases and inflammatory diseases.

Authors:  Mi Hee Park; MiRan Jo; Yu Ri Kim; Chong-Kil Lee; Jin Tae Hong
Journal:  Pharmacol Ther       Date:  2016-04-26       Impact factor: 12.310

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.